MSD concludes Terns acquisition to expand CML pipeline
Pharmaceutical Business Review
Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD.
pharminent
May 6, 2026 (Last updated: May 6, 2026)
Pharmaceutical Business Review
Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD.